Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022.
Zhaoquan WangHe JiangXianwu PangJianjun LiShujia LiangJinghua HuangDejian LiWenxuan HouNi ChenGuanghua LanPublished in: The Journal of antimicrobial chemotherapy (2024)
HIV-1 PDR and ADR prevalence in China exhibited diverse epidemiological characteristics, underscoring the importance of ongoing national monitoring of PDR, ADR and subtype; patient education on adherence; and personalized regimens.
Keyphrases
- antiretroviral therapy
- hiv positive
- hiv infected
- hiv testing
- human immunodeficiency virus
- hepatitis c virus
- hiv aids
- men who have sex with men
- quality improvement
- adverse drug
- healthcare
- risk factors
- case report
- south africa
- emergency department
- type diabetes
- adipose tissue
- metabolic syndrome
- weight loss
- insulin resistance
- health insurance
- electronic health record